-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents
-- The study did not show statistically-significant progression-free or overall survival benefit with ibrutinib in combination versus the placebo combination study arm
-- Metastatic pancreatic cancer is one of the most aggressive and deadliest forms of cancer, with an estimated 5-year survival of less than 5 percent1
-- IMBRUVICA is currently approved by the U.S. FDA in six disease areas with nine treatment indications and has cumulatively treated more than 135,000 patients globally in clinical practice and trials
PR Newswire
NORTH CHICAGO, Ill., Jan. 18, 2019
